GALR2 and central nervous system cancer: Although GAL2-R-immunoreacitivity was undetectable in tumor cells of glioma and pituitary adenoma, 27% of glioma samples, particularly astrocytoma (WHO grade I-III), and 44% of pituitary adenomas revealed a small proportion of GAL2-R-positive neutrophilic granulocytes (Figure 8C).